Table 4

Number of children enrolled in the retrospective cohort study who were reported by primary care givers as having symptoms, or prior vaccination, and receiving trivalent inactivated influenza vaccine (TIV) in 2010, by brand and formulation

		Percentage of children with symptom				CF versus Influvac	CF versus Influvac (controlling for age)
		Fluvax (n=109)	Fluvax Junior (n=100)	Combined Fluvax and Fluvax Junior (CF) (n=209)	Influvac (n=110)	Univariate χ² p value	OR (95% CI)	p Value
Reported symptom	Fever^*	52.3	61.0	56.5	17.3	0.00001	5.1 (2.9 to 9.2)	0.0001
	Fatigue	29.4	37.0	33.0	10.9	0.0001	3.5 (1.8 to 7.0)	0.0003
	Vomiting	14.7	20.0	17.2	2.7	0.0001	6.0 (1.8 to 20.3)	0.0037
	Rigours	11.9	19.0	15.3	0.9	0.0006	16.0 (2.1 to 119.5)	0.0070
	Swelling	12.8	13.0	12.9	10.9	0.6	1.1 (0.5 to 2.3)	0.7914
	Diarrhoea	6.4	4.0	5.3	0.9	0.052	5.3 (0.7 to 43.0)	0.1160
	Rash	5.5	2.0	3.8	0.9	0.14	3.8 (0.5 to 31.2)	0.2193
	Headache	3.7	3.0	3.4	0.9	0.18	4.3 (0.5 to 37.5)	0.1843
	Convulsions	2.8	0.0	1.4	0.0	0.2	NA
	Significant SFAE	22.9	36.0	29.2	4.5	0.0001	7.0 (2.7 to 18.3)	0.0001

		Percentage of children answering ‘Yes’ (n)				CF versus Influvac	CF versus Influvac (controlling for age)
		Fluvax (n=109)	Fluvax Junior (n=100)	Combined Fluvax and Fluvax Junior (CF) (n=209)	Influvac (n=110)	Univariate χ² p value	OR (95% CI)	p Value
Prior influenza vaccination history	Had monovalent 2009 H1N1 pandemic influenza vaccine? (n=104)	15.4 (104)	15.6 (96)	15.5 (200)	19.6 (102)	0.37	0.9 (0.4 to 1.6)	0.64
Prior influenza vaccination history	Had seasonal influenza vaccine before 2010? (n=107)	50.5 (107)	49 (100)	49.8 (207)	57.5 (108)	0.19	1.5 (0.9 to 2.6)	0.16

SFAE, significant febrile adverse event (defined as fever ≥39^°C and/or rigours and/or a febrile convulsion).
* Self-reported fever, whether measured or not.